Pathological evaluation of differentiated thyroid cancer in patients with positive serum thyroglobulin and negative iodine scan

被引:0
|
作者
Ansari, M. [1 ]
Babaei, A. A. [1 ]
Shafiei, B. [2 ]
Javadi, H. [3 ]
Assadi, M. [4 ]
Nabipour, I. [4 ]
Asli, I. N. [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Imam Hossein Hosp, Dept Nucl Med, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Dept Nucl Med, Tehran, Iran
[3] Golestan Univ Med Sci, GRCGH, Gorgan, Iran
[4] Bushehr Univ Med Sci, Persian Gulf Nucl Med Res Ctr, Bushehr, Iran
关键词
Differentiated thyroid cancer (DTC); Pathologic subtype; Papillary thyroid cancer (PTC); Follicular thyroid cancer (FTC); Positive thyroglobulin and negative iodine scan. (Tg plus /WBS-); WHOLE-BODY SCAN; POSITRON-EMISSION-TOMOGRAPHY; RADIOIODINE THERAPY; I-131; CARCINOMA; TG;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: There is no investigation that emphasizes the pathology of DTC (differentiated thyroid cancer) patients with positive Tg and negative iodine scan. The present study was performed to assess the pathology of these patients. MATERIALS AND METHODS: In this retrospective study, the records of 500 patients with differentiated thyroid cancer between June 2005 and November 2011 were assessed, and those patients who had elevated serum thyroglobulin (Tg) with a negative whole body I-131 scan (Tg+/WBS-) were included in the study. Patients were followed for clinical and pathological findings of thyroid cancer, including type, variant, local invasion and cervical lymph node metastasis, and serum Tg, TgAb, and TSH levels. RESULTS: A total of 38 patients, including 31 (81.6%) females and 7 (18.4) males with a mean age of 44.2 +/- 15.6 years (range, 14 to 77 yrs) took part in the study. All 38 patients had the papillary type of differentiated thyroid cancer (PCDTC), and none had the follicular type of differentiated thyroid cancer (FCDTC). For the variant type of PTC in 16 patients, it was found that 7 were classic type (43.8%), 7 were follicular type (43.8%), and 2 were tall cell (12.4%) for papillary thyroid cancer. In 22 patients no distinct variant had been reported. CONCLUSIONS: This report demonstrated that all of the 38 patients were PTC (100%), which is different from other previous studies. It may be concluded that the overall pathologic subtypes changes of DTC could mainly be due to the iodine fortification program in various geographic regions. The relationship between DTC pathologic subtypes and frequency of Tg+/WBS-condition was difficult to assess in this work. Therefore, further studies are required to evaluate this issue.
引用
收藏
页码:1925 / 1929
页数:5
相关论文
共 50 条
  • [1] Radioactive Iodine (I-131) Therapy for Thyroglobulin Positive, Scan Negative Differentiated Thyroid Cancer.
    Alzahrani, Ali S.
    Alshaikh, Omalkhaire
    Al-Shehri, Sameerah
    Farhat, Rafif
    [J]. ENDOCRINE REVIEWS, 2010, 31 (03)
  • [2] Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer
    Kloos, Richard T.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (05): : 1519 - 1525
  • [3] Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma
    Shinohara, Shogo
    Kikuchi, Masahiro
    Suehiro, Atsushi
    Kishimoto, Ippei
    Harada, Hiroyuki
    Hino, Megumu
    Ishihara, Takashi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (05) : 427 - 432
  • [4] Efficacy of radioiodine therapy in the treatment of elevated serum thyroglobulin in patients with differentiated thyroid carcinoma and negative whole-body iodine scan
    Saghari, Mohsen
    Gholamrezanezhad, Ali
    Mirpour, Sahar
    Eftekhari, Mohammad
    Takavar, Abbas
    Fard-Esfahani, Armaghan
    Fallahi, Babak
    Beiki, Davood
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2006, 27 (07) : 567 - 572
  • [5] Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: Including comments on the role of serum thyroglobulin monitoring in tumor surveillance
    Fatourechi, V
    Hay, ID
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2000, 30 (02) : 107 - 114
  • [6] Evaluation of iodine-131 therapy for differentiated thyroid carcinoma patients with elevated thyroglobulin and negative iodine-131 whole body scan.
    Tian, R
    Qin, SW
    Kuang, RA
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 334P - 334P
  • [7] Therapeutic Response Prediction Using Iodine Scan-Corrected Serum Thyroglobulin in Patients with Differentiated Thyroid Carcinoma
    Kwon, S.
    Chowdhury, M.
    Jeon, S.
    Kim, A.
    Kim, J.
    Song, H.
    Bom, H.
    Min, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S659 - S659
  • [8] Radioiodine therapy for differentiated thyroid carcinoma with thyroglobulin positive and radioactive iodine negative metastases
    Ma, Chao
    Kuang, Anren
    Xie, Jiawei
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [9] MANAGEMENT OF PATIENTS WITH DIFFERENTIATED THYROID-CANCER WHO HAVE POSITIVE SERUM THYROGLOBULIN LEVELS AND NEGATIVE RADIOIODINE SCANS
    CLARK, OH
    HOELTING, T
    [J]. THYROID, 1994, 4 (04) : 501 - 505
  • [10] FDG PET scan in the follow-up of differentiated thyroid cancer: Contribution for patients with positive serum thyroglobulin levels and negative therapeutic radioiodine scans.
    Helal, BO
    Merlet, P
    Toubert, ME
    Daou, D
    Saidi, L
    Maziere, B
    Syrota, A
    [J]. JOURNAL OF NUCLEAR MEDICINE, 1999, 40 (05) : 102P - 102P